Marc Bernarducci

During my SVP, Field Solutions – Clinical tenure at EVERSANA, we refined our strategic approach to the recruitment, deployment, and leadership of our current field medical team business across diverse partner profiles. In addition, our share of voice was amplified cross-functionally, especially within the Business Development, COMPLETE Commercialization, and internal Medical Affairs business units. As HEAD, FIELD MEDICAL – US FOR RESVERLOGIX, we are excited to leverage our scientific acumen, expertise, and platform, as part of our North American Complete Commercialization partnership with EVERSANA, which was publicly announced in June 2021.

Resverlogix US Field Medical Affairs will complement a Global Medical Affairs infrastructure, upon which Resverlogix will develop and execute its commercialization strategy for its investigational lead asset, apabetalone. Collaborating with EVERSANA-Canada, we will begin with the North American COVID clinical development program, which consists of Phase 2 (Canada) and 3 (USA) initiatives.

EVERSANA will also work seamlessly with Resverlogix Field Medical through each stage of apabetalone’s life cycle in this space to distill and transform medical insights into well-informed strategic adaptation. The overarching goal is optimizing the scientific narrative and environment for apabetalone, as it evolves through all the stages of its life cycle in multiple therapeutic areas (e.g., cardiovascular, pulmonary, nephrology, neurology, infectious disease). "